Want to see JP:6869 full AI Analyst Report?
6869 Stock Chart & Stats
¥1530.00
¥19.50(1.21%)
At close: 4:00 PM EDT
¥1530.00
¥19.50(1.21%)
Day’s Range― - ―
52-Week Range¥1,246.00 - ¥2,529.50
Previous CloseN/A
Volume1.58M
Average Volume (3M)2.38M
Market Cap
¥997.15B
Enterprise Value¥836.79K
Total Cash (Recent Filing)¥84.12B
Total Debt (Recent Filing)¥70.48B
Price to Earnings (P/E)28.1
Beta0.14
Next Earnings
Aug 07, 2026EPS Estimate
9.74Next Dividend Ex-DateN/A
Dividend Yield2.38%
Share Statistics
EPS (TTM)56.89
Shares Outstanding629,480,100
10 Day Avg. Volume2,693,210
30 Day Avg. Volume2,377,620
Financial Highlights & Ratios
PEG Ratio-0.71
Price to Book (P/B)1.69
Price to Sales (P/S)1.71
P/FCF Ratio20.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)67.27
Revenue Forecast (FY)¥535.73B
Bulls Say, Bears Say
Bulls Say
Recurring Revenue Model (reagents & Service)Sysmex's core model pairs capital instrument sales with high-margin, recurring reagent and service revenues tied to installed instruments. This creates durable revenue visibility and customer lock-in through validated consumables and multi-year service relationships, supporting steady cash flow and margin resilience over time.
Consistently Healthy Historical MarginsSustained gross and net margins reflect durable pricing power and operational efficiency from a product mix skewed to instruments plus recurring consumables. Healthy margins provide a buffer in downturns, funding R&D and service infrastructure, and underpin long-term profitability even if top-line growth slows.
Conservative Balance Sheet And Equity GrowthA large, growing equity base and historically low leverage give Sysmex financial flexibility to fund R&D, absorb temporary earnings shocks, and pursue selective investments. This conservative capital structure supports long-term stability and reduces solvency risk during cyclical pressure.
Bears Say
Sharp 2026 Revenue And Profit DeteriorationA pronounced step-down in 2026 revenue and profits risks slowing instrument placements and the downstream pull-through of reagents and services that drive recurring revenues. If the weakness persists, it can structurally reduce future installed-base growth, margin leverage, and multi-year revenue visibility.
Rising Total Debt In Recent YearsAlthough leverage remains moderate versus equity, the steady increase in nominal debt raises fixed financial obligations and reduces balance-sheet optionality. If earnings and cash flow remain pressured, higher debt can constrain investments, elevate interest exposure, and limit strategic flexibility over the medium term.
Volatile Free Cash Flow And Uneven Cash ConversionIrregular free cash flow from working-capital swings and investment timing complicates capital allocation and weakens predictability. Persistent FCF volatility can hinder consistent funding of capex, R&D, dividends or buybacks, and makes the firm more sensitive to operational or demand shocks over the medium term.
Sysmex News
6869 FAQ
What was Sysmex Corporation’s price range in the past 12 months?
Sysmex Corporation lowest stock price was ¥1246.00 and its highest was ¥2529.50 in the past 12 months.
What is Sysmex Corporation’s market cap?
Sysmex Corporation’s market cap is ¥997.15B.
When is Sysmex Corporation’s upcoming earnings report date?
Sysmex Corporation’s upcoming earnings report date is Aug 07, 2026 which is in 4 days.
How were Sysmex Corporation’s earnings last quarter?
Sysmex Corporation released its earnings results on May 14, 2026. The company reported ¥2.84 earnings per share for the quarter, missing the consensus estimate of ¥5.931 by -¥3.091.
Is Sysmex Corporation overvalued?
According to Wall Street analysts Sysmex Corporation’s price is currently Overvalued.
Does Sysmex Corporation pay dividends?
Sysmex Corporation pays a Annually dividend of ¥20 which represents an annual dividend yield of 2.38%. See more information on Sysmex Corporation dividends here
What is Sysmex Corporation’s EPS estimate?
Sysmex Corporation’s EPS estimate is 9.74.
How many shares outstanding does Sysmex Corporation have?
Sysmex Corporation has 629,480,100 shares outstanding.
What happened to Sysmex Corporation’s price movement after its last earnings report?
Sysmex Corporation reported an EPS of ¥2.84 in its last earnings report, missing expectations of ¥5.931. Following the earnings report the stock price went up 0.075%.
Which hedge fund is a major shareholder of Sysmex Corporation?
Currently, no hedge funds are holding shares in JP:6869
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sysmex Corporation
Sysmex Corporation, headquartered in Kobe, Japan, and established in 1968 (originally known as TOA Medical Electronics Co., Ltd. until its rebranding in October 1998), specializes in the development, manufacturing, and global distribution of advanced diagnostic instrumentation, chemical reagents, and associated software. Its comprehensive product portfolio addresses various diagnostic needs. In hematology, it offers instruments for both three-part and five-part white blood cell differentiation, alongside efficient transport systems designed for high-volume laboratory testing. For urinalysis, the company provides systems capable of analyzing urine formed sediment. Its offerings extend to automated immunochemistry systems, which are adept at performing assays with minute sample quantities, complemented by reagents for detecting infectious diseases and tumor markers. Sysmex also manufactures flow cytometers, crucial for the analysis involved in diagnosing conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Beyond these core areas, the company is deeply involved in oncology diagnostics, developing systems for detecting cancer lymph node metastasis and cancer genome profiling, as well as offering cytogenetic testing and specialized lab assay services. Sysmex also contributes to digital medicine through the development and sale of software for diagnostic information systems, alongside the creation, operation, and maintenance of IT solutions, platforms, and applications in this field. Its activities further encompass the development and sale of nucleic acid analogs, the full lifecycle management (marketing, development, design, manufacture, sale, and after-sales support) of medical robots, and the distribution and post-sales support for medical devices and reagents used in biotechnology, medical technology, and molecular cell analysis. Sysmex serves a diverse client base, including national, public, and private hospitals, universities, research institutes, and other medical facilities. With a robust international presence, the company exports its products to approximately 190 countries worldwide. Demonstrating its commitment to innovation, Sysmex Corporation maintains a strategic alliance with QIAGEN N.V. for the collaborative development and commercialization of cancer companion diagnostics utilizing Plasma-Safe-SeqS technology.